タンパク質阻害剤の世界市場レポート 2025年

タンパク質阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）9.0％で1,252億6,000万米ドルに成長します。予測期間の成長は、精密医療、免疫療法、薬剤の組み合わせ、高齢化などに起因すると考えられます。予測期間における主な動向には、データ共有と連携、持続可能性とESG、個別化医療、適応型臨床試験などがあります。

慢性疾患の罹患率の上昇は、予測期間中のタンパク質阻害剤市場の成長を促進すると予想されます。がん、心血管疾患、自己免疫疾患などの疾患がますます一般的になっています。例えば、2024年6月、英国の公的医療制度であるナショナル・ヘルスケア・サービス（National Health Service）は、2023年に一般開業医に登録された非糖尿病性高血糖症、または糖尿病予備群の患者は361万5,330人であったと報告しました。これは、2022年の306万5,825人からの大幅な増加であり、約18％の増加に相当します。その結果、慢性疾患に罹患する個人数の増加が、市場におけるタンパク質阻害剤の需要を高める可能性が高いです。

個別化医療に対する需要の高まりが、今後のタンパク質阻害剤市場の成長を牽引すると予測されます。個別化医療は、個人のユニークな遺伝子構成に基づいて治療をカスタマイズし、より効果的で正確なヘルスケア介入をもたらします。タンパク質阻害剤は、その人の遺伝子プロファイルに応じて特定のタンパク質を標的として病気に対処することで、個別化医療において重要な役割を果たしています。例えば、2024年2月、米国を拠点とする専門家会員組織である個別化医療連合（Personalized Medicine Coalition）は、FDAが2023年に希少疾患患者のための新しい個別化治療を16件承認し、2022年の6件から大幅に増加したと報告しました。承認された35の新規分子生物学的製剤（NME）のうち、約34％にあたる12が、個別化医療連合（PMC）によって個別化医薬品に分類されています。このように、個別化医療への関心の高まりが、タンパク質阻害剤市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界タンパク質阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のタンパク質阻害剤市場：成長率分析
• 世界のタンパク質阻害剤市場の実績：規模と成長, 2019-2024
• 世界のタンパク質阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界タンパク質阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のタンパク質阻害剤市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質キナーゼ阻害剤
• モノクローナル抗体
• その他の製品
• 世界のタンパク質阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 炎症性疾患
• その他の用途
• 世界のタンパク質阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 独立系薬局
• オンライン薬局
• 世界のタンパク質阻害剤市場タンパク質キナーゼ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的キナーゼ阻害剤
• 非選択的キナーゼ阻害剤
• 小分子キナーゼ阻害剤
• 生物学的キナーゼ阻害剤
• 世界のタンパク質阻害剤市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• キメラモノクローナル抗体
• ヒト化モノクローナル抗体
• 完全ヒトモノクローナル抗体
• 結合モノクローナル抗体
• 世界のタンパク質阻害剤市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペプチド阻害剤
• タンパク質分解技術
• 低分子阻害剤
• 併用療法製品

第7章 地域別・国別分析

• 世界のタンパク質阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のタンパク質阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• タンパク質阻害剤市場：競合情勢
• タンパク質阻害剤市場：企業プロファイル
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Apotex Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Abbott Laboratories
• Amgen Inc.
• Baxter International Inc.
• Merck & Co. Inc.
• Interprotein Corporation
• AbbVie Inc.
• Bristol Myers Squibb Company
• Galapagos NV
• Priovant Therapeutics Inc.
• Tempus Labs Inc.
• ReCode Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• タンパク質阻害剤市場2029：新たな機会を提供する国
• タンパク質阻害剤市場2029：新たな機会を提供するセグメント
• タンパク質阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Protein inhibitors are compounds that disrupt the cellular process involved in creating new proteins. They specifically target the steps in protein synthesis within cells, operating at the level of the ribosome. This is possible due to the distinct structural differences between prokaryotic and eukaryotic ribosomes.

The primary types of protein inhibitors include protein kinase inhibitors, monoclonal antibodies, and other related compounds. Monoclonal antibodies, created in laboratories, mimic or enhance the immune system's attack on unwanted cells, such as cancer cells, effectively acting as substitute antibodies. These protein inhibitors find application in treating conditions like oncology (cancer) and inflammatory diseases. They are distributed through various channels including hospital pharmacies, independent pharmacies, and online pharmacies to reach patients in need of these treatments.

The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The protein inhibitors market size has grown strongly in recent years. It will grow from $80.99 billion in 2024 to $88.74 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to drug discovery, drug development, cancer treatment, regulatory approvals.

The protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $125.26 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to precision medicine, immunotherapy, drug combinations, aging population. Major trends in the forecast period include data sharing and collaboration, sustainability and ESG, personalized medicine, and adaptive clinical trials.

The rising incidence of chronic diseases is expected to drive the growth of the protein inhibitors market during the forecast period. Conditions such as cancer, cardiovascular diseases, and autoimmune disorders are becoming increasingly common. For example, in June 2024, the National Health Service, a publicly funded healthcare system in England, reported that there were 3,615,330 individuals registered with a general practitioner who had non-diabetic hyperglycemia, or pre-diabetes, in 2023. This represents a significant increase from 3,065,825 in 2022, amounting to an increase of nearly 18%. Consequently, the growing number of individuals suffering from chronic diseases is likely to enhance the demand for protein inhibitors in the market.

The increasing demand for personalized medicine is anticipated to drive the growth of the protein inhibitors market in the future. Personalized medicine customizes medical treatments based on an individual's unique genetic composition, resulting in more effective and precise healthcare interventions. Protein inhibitors play a vital role in personalized medicine by targeting specific proteins to address diseases according to a person's genetic profile. For example, in February 2024, the Personalized Medicine Coalition, a professional membership organization based in the US, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant rise from six in 2022. Of the 35 new molecular entities (NMEs) approved, about 34% or 12 are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the growing interest in personalized medicine is fueling the expansion of the protein inhibitors market.

Leading companies in the protein inhibitor market are increasingly focusing their investments on strategic initiatives, including partnerships and collaborations, to develop new drugs that align with market demand. These strategic alliances enable companies to broaden their product portfolios and expand their geographical reach. For example, in July 2024, Genentech Inc., a US-based biotechnology firm, entered into a collaboration with Relay Therapeutics to develop protein inhibitors, particularly the SHP2 inhibitor RLY-1971 (also known as migoprotafib or GDC-1971). This partnership started with an initial investment of $75 million in 2021, accompanied by an additional $45 million in milestone payments, bringing the total investment to over $120 million before its conclusion. The collaboration aimed to investigate the therapeutic potential of RLY-1971 in conjunction with Genentech's KRAS G12C inhibitor, GDC-6036, for treating advanced solid tumors, including colorectal cancer.

Key players in the protein inhibitors market are prioritizing the development of tyrosine kinase 2 (TYK2) inhibitors, positioning themselves competitively. TYK2 inhibitors, instrumental in treating specific autoimmune conditions by blocking the TYK2 enzyme involved in immune system responses, are a significant focus. For instance, Bristol-Myers Squibb Company gained FDA approval in September 2022 for Sotyktu (deucravacitinib), an oral medication specifically for adults with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. Sotyktu stands as the first oral treatment with selective inhibition of TYK2 through allosteric mechanisms, marking a significant advancement in this segment of the market.

In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus.

Major companies operating in the protein inhibitors market include Bayer AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Novartis International AG, GlaxoSmithKline plc, Pfizer Inc., Boehringer Ingelheim International GmbH, Abbott Laboratories, Amgen Inc., Baxter International Inc., Merck & Co. Inc., Interprotein Corporation, AbbVie Inc., Bristol Myers Squibb Company, Galapagos NV, Priovant Therapeutics Inc., Tempus Labs Inc., ReCode Therapeutics Inc., Satellite Bio Inc., Ambagon Therapeutics Inc., Biogen Inc., Eli Lilly and Company, Gilead Sciences Inc., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Inc., Lonza Group AG, Catalent Inc., Thermo Fisher Scientific Inc., Charles River Laboratories International Inc., WuXi AppTec Co. Ltd.

North America was the largest region in the protein inhibitors market in 2024. The regions covered in the protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Protein Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on protein inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for protein inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The protein inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Protein Kinase Inhibitors; Monoclonal Antibody; Other Products
• 2) By Application: Oncology; Inflammatory Diseases; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Independent Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Protein Kinase Inhibitors: Selective Kinase Inhibitors; Non-selective Kinase Inhibitors; Small Molecule Kinase Inhibitors; Biologic Kinase Inhibitors
• 2) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies; Conjugated Monoclonal Antibodies
• 3) By Other Products: Peptide Inhibitors; Protein Degradation Technologies; Small Molecule Inhibitors; Combination Therapy Products
• Companies Mentioned: Bayer AG; AstraZeneca plc; F. Hoffmann-La Roche Ltd.; Teva Pharmaceutical Industries Ltd.; Apotex Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Protein Inhibitors Market Characteristics

3. Protein Inhibitors Market Trends And Strategies

4. Protein Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Protein Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Protein Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Protein Inhibitors Market Growth Rate Analysis
• 5.4. Global Protein Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Protein Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Protein Inhibitors Total Addressable Market (TAM)

6. Protein Inhibitors Market Segmentation

• 6.1. Global Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Kinase Inhibitors
• Monoclonal Antibody
• Other Products
• 6.2. Global Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Inflammatory Diseases
• Other Applications
• 6.3. Global Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Independent Pharmacies
• Online Pharmacies
• 6.4. Global Protein Inhibitors Market, Sub-Segmentation Of Protein Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Kinase Inhibitors
• Non-selective Kinase Inhibitors
• Small Molecule Kinase Inhibitors
• Biologic Kinase Inhibitors
• 6.5. Global Protein Inhibitors Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chimeric Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Fully Human Monoclonal Antibodies
• Conjugated Monoclonal Antibodies
• 6.6. Global Protein Inhibitors Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptide Inhibitors
• Protein Degradation Technologies
• Small Molecule Inhibitors
• Combination Therapy Products

7. Protein Inhibitors Market Regional And Country Analysis

• 7.1. Global Protein Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Protein Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Protein Inhibitors Market

• 8.1. Asia-Pacific Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Protein Inhibitors Market

• 9.1. China Protein Inhibitors Market Overview
• 9.2. China Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Protein Inhibitors Market

• 10.1. India Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Protein Inhibitors Market

• 11.1. Japan Protein Inhibitors Market Overview
• 11.2. Japan Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Protein Inhibitors Market

• 12.1. Australia Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Protein Inhibitors Market

• 13.1. Indonesia Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Protein Inhibitors Market

• 14.1. South Korea Protein Inhibitors Market Overview
• 14.2. South Korea Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Protein Inhibitors Market

• 15.1. Western Europe Protein Inhibitors Market Overview
• 15.2. Western Europe Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Protein Inhibitors Market

• 16.1. UK Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Protein Inhibitors Market

• 17.1. Germany Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Protein Inhibitors Market

• 18.1. France Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Protein Inhibitors Market

• 19.1. Italy Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Protein Inhibitors Market

• 20.1. Spain Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Protein Inhibitors Market

• 21.1. Eastern Europe Protein Inhibitors Market Overview
• 21.2. Eastern Europe Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Protein Inhibitors Market

• 22.1. Russia Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Protein Inhibitors Market

• 23.1. North America Protein Inhibitors Market Overview
• 23.2. North America Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Protein Inhibitors Market

• 24.1. USA Protein Inhibitors Market Overview
• 24.2. USA Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Protein Inhibitors Market

• 25.1. Canada Protein Inhibitors Market Overview
• 25.2. Canada Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Protein Inhibitors Market

• 26.1. South America Protein Inhibitors Market Overview
• 26.2. South America Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Protein Inhibitors Market

• 27.1. Brazil Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Protein Inhibitors Market

• 28.1. Middle East Protein Inhibitors Market Overview
• 28.2. Middle East Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Protein Inhibitors Market

• 29.1. Africa Protein Inhibitors Market Overview
• 29.2. Africa Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Protein Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Protein Inhibitors Market Competitive Landscape
• 30.2. Protein Inhibitors Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Apotex Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Protein Inhibitors Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. GlaxoSmithKline plc
• 31.3. Pfizer Inc.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Abbott Laboratories
• 31.6. Amgen Inc.
• 31.7. Baxter International Inc.
• 31.8. Merck & Co. Inc.
• 31.9. Interprotein Corporation
• 31.10. AbbVie Inc.
• 31.11. Bristol Myers Squibb Company
• 31.12. Galapagos NV
• 31.13. Priovant Therapeutics Inc.
• 31.14. Tempus Labs Inc.
• 31.15. ReCode Therapeutics Inc.

32. Global Protein Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Protein Inhibitors Market

34. Recent Developments In The Protein Inhibitors Market

35. Protein Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Protein Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Protein Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Protein Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer